Khalid Mezzi
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Oncology top 10%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Hematology 24
- Multiple Myeloma Research and Treatments 23
- Chronic Myeloid Leukemia Treatments 2
-
- Protein Degradation and Inhibitors 13
- Cancer therapeutics and mechanisms 2
- Co-authors
- Emma Scott (2 shared papers)Ajai Chari (4 shared papers)Saad Z. Usmani (2 shared papers)Nina Shah (1 shared paper)David S. Siegel (9 shared papers)Noopur Raje (3 shared papers)Madhav V. Dhodapkar (1 shared paper)Adam D. Cohen (2 shared papers)
- Journals
- Blood (9 papers)Leukemia (2 papers)Clinical Cancer Research (1 paper)The Oncologist (1 paper)HemaSphere (1 paper)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Khalid Mezzi
26 papers receiving 810 citations
Khalid Mezzi's Hit Papers
Peers
Comparison fields: 5 of 63
- Hematology 480
- Oncology 397
- Immunology 135
- Genetics 57
- Molecular Biology 378
Countries citing papers authored by Khalid Mezzi
This map shows the geographic impact of Khalid Mezzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Mezzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Mezzi more than expected).
Fields of papers citing papers by Khalid Mezzi
This network shows the impact of papers produced by Khalid Mezzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Mezzi. The network helps show where Khalid Mezzi may publish in the future.
Co-authors
The 25 scholars most cited alongside Khalid Mezzi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Hit paper breakdown → | 2020 | 328 |
| 2 | 2020 | 158 | |
| 3 | 2019 | 84 | |
| 4 | 2019 | 45 | |
| 5 | 2018 | 29 | |
| 6 | 2020 | 26 | |
| 7 | 2021 | 26 | |
| 8 | 2016 | 24 | |
| 9 | 2013 | 19 | |
| 10 | 2017 | 14 | |
| 11 | 2020 | 13 | |
| 12 | 2019 | 13 | |
| 13 | 2024 | 11 | |
| 14 | 2016 | 7 | |
| 15 | 2018 | 6 | |
| 16 | 2024 | 5 | |
| 17 | 2017 | 4 | |
| 18 | 2019 | 3 | |
| 19 | 2017 | 3 | |
| 20 | 2017 | 2 |
About Khalid Mezzi
Khalid Mezzi is a scholar working on Hematology, Molecular Biology, Oncology, Public Health, Environmental and Occupational Health and Genetics, having authored 26 papers that have together received 827 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (13 papers), Cancer Treatment and Pharmacology (4 papers), CAR-T cell therapy research (3 papers), Chronic Myeloid Leukemia Treatments (2 papers), Peptidase Inhibition and Analysis (2 papers), Cancer therapeutics and mechanisms (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Hematology (480 citations), Oncology (397 citations), Immunology (135 citations), Genetics (57 citations) and Molecular Biology (378 citations). Khalid Mezzi has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Emma Scott, Ajai Chari, Saad Z. Usmani, Nina Shah, David S. Siegel, Noopur Raje, Madhav V. Dhodapkar, Adam D. Cohen, Jessica Fowler and Aaron S. Rosenberg. Their work appears in journals such as Blood, Leukemia, Clinical Cancer Research, The Oncologist and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.